

A'cont
(a) an oral dosage form comprising a PDE5 inhibitor having an IC_{50} for the inhibition of PDE5 less than 10 nM, and sufficient bioavailability to be effective in about 1 to about 10 mg unit oral dosages;

(b) a package insert providing that the PDE5 inhibitor is useful to treat sexual dysfunction in a patient in need thereof by utilizing a chronic dosing regimen for at least three days; and ?

(c) a container.

Sub B1
A2
5. (Amended) The article of manufacture of claim 1, 2, 3, or 4, wherein the PDE5 inhibitor further has

(i) at least a 100 fold differential in IC_{50} values for the inhibition of PDE5 versus PDE6, and

(ii) at least 1000 fold differential in IC_{50} values for the inhibition of PDE5 versus PDE1c.

6. (Amended) The article of claim 1, 2, 3, or 4 wherein the oral dosage form comprises about 1 mg, about 2 mg, about 5 mg, or about 10 mg, of the PDE5 inhibitor..

7. (Amended) The article of claim 1, 2, 3, or 4 wherein the chronic dosing regimen is a daily dosing regimen.

8. (Amended) The article of claim 1, 2, 3, or 4 wherein the chronic dosing regimen comprises administration of about 1 mg/day to about 10 mg/day of the PDE5 inhibitor.

9. (Amended) The article of claim 1, 2, 3, or 4 wherein the package insert provides a maximum dosage of the PDE5 inhibitor of about 10 mg per day.

10. (Amended) The article of claim 1, 2, 3, or 4 wherein the PDE5 inhibitor is selected from the group consisting of

(6R,12aR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione;

(3S,6R,12aR)-2,3,6,7,12,12a-hexahydro-2,3-dimethyl-6-(3,4-methylenedioxyphenyl)pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione;

5-(2-ethoxy-5-morpholinoacetylphenyl)-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one;

5-(5-morpholinoacetyl-2-n-propoxyphenyl)-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one;

5-[2-allyloxy-5-(4-methyl-1-piperazinylsulphonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one;

5-{2-ethoxy-5-[4-(2-propyl)-1-piperazinylsulphonyl]phenyl}-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one;

5-{2-ethoxy-5-[4-(2-hydroxyethyl)-1-piperazinylsulphonyl]phenyl}-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one;

5-{5-[4-(2-hydroxyethyl)-1-piperazinylsulphonyl]-2-n-propoxyphenyl}-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one;

5-[2-ethoxy-5-(4-methyl-1-piperazinylcarbonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one; and

B1
A2 cont

5-[2-ethoxy-5-(1-methyl-2-imidazolyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one.

12. (Amended) The article of claim 1, 2, 3, or 4 wherein the PDE5 inhibitor is selected from the group consisting of sildenafil and vardenafil.

A3 Sub BB

13. (Amended) The article of claim 1, 2, 3, or 4, wherein the PDE5 inhibitor has the structure

